Literature DB >> 9820533

Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization.

M Mancini1, M Hadchouel, P Tiollais, M L Michel.   

Abstract

The immunotherapeutic effect of DNA-mediated immunization against chronic hepatitis B virus (HBV) infection has been evaluated in transgenic mice expressing the sequences that code for the envelope proteins of HBV in the liver. In this model of HBV chronic carriers, a single i.m. injection of plasmid DNA encoding HBV envelope proteins is sufficient to generate specific immune responses leading to the clearance of the transgene expression product and the control of HBV mRNA. The relative contributions of the T cell subpopulations induced by DNA immunization were examined using adoptive transfer experiments. It was shown that either CD8+ or CD4+ T lymphocytes from immunocompetent DNA-immunized animals were sufficient to control viral gene expression in the livers of the recipient transgenic mice. This effect was mediated by a cytokine-dependent mechanism common to both T cell subpopulations; this mechanism did not require cell lysis, but did involve the production of IFN-gamma by the activated T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

2.  Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice.

Authors:  Ren Zhu; Maryline Mancini-Bourgine; Xiao Ming Zhang; Florence Bayard; Qiang Deng; Marie-Louise Michel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

3.  CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Authors:  E Malanchère-Brès; P J Payette; M Mancini; P Tiollais; H L Davis; M L Michel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.

Authors:  D Marsac; D Loirat; C Petit; O Schwartz; M-L Michel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.

Authors:  Anna D Kosinska; Ejuan Zhang; Mengji Lu; Michael Roggendorf
Journal:  Hepat Res Treat       Date:  2010-09-07

Review 6.  The state of gene therapy research in Africa, its significance and implications for the future.

Authors:  P Arbuthnot; M B Maepa; A Ely; M S Pepper
Journal:  Gene Ther       Date:  2017-07-10       Impact factor: 5.250

7.  Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling.

Authors:  Meina He; Dan Su; Qinghong Liu; Wenjuan Gao; Youmin Kang
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.